← Back to Search

Central Nervous System Stimulant

Stimulant Medication for ADHD

Phase 2
Recruiting
Led By Cynthia M Hartung, Ph.D.
Research Sponsored by University of Wyoming
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ADHD Participants: Must report a prior diagnosis of ADHD and self-report five or more inattention (IA) symptoms on the DSM-5 Symptom Checklist on the pre-screener
Healthy Participants: Must disavow ever being diagnosed with ADHD, report 3 or fewer IA symptoms and 3 or fewer hyperactivity/impulsivity (HI) symptoms on the DSM-5 ADHD Symptom Checklist in the pre-screener and are an age and sex match of an ADHD group participant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up completed the day after each experimental appointment over a period of two weeks
Awards & highlights

Study Summary

This trialwill examine if stimulants improve executive functioning in college students with ADHD but not those without, to better understand efficacy and prevent misuse.

Who is the study for?
This trial is for college students aged 18-29 with ADHD who have been previously diagnosed and report significant inattention symptoms. They must be native English speakers, not pregnant, non-smokers, and not using conflicting medications or substances. Healthy peers without ADHD are also included as controls if they match an ADHD participant's age and sex.Check my eligibility
What is being tested?
The study tests the immediate effects of Adderall IR (a stimulant medication) on executive functioning in college students with ADHD compared to a placebo. The goal is to see if Adderall improves attention and working memory better than no treatment at all.See study design
What are the potential side effects?
Potential side effects of Adderall may include nervousness, restlessness, difficulty sleeping, dry mouth, headache, changes in sex drive or ability; gastrointestinal issues like diarrhea or constipation; and potentially more serious heart-related issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with ADHD and experience five or more symptoms of inattention according to the DSM-5 Symptom Checklist.
Select...
If you are a healthy participant, you must not have been diagnosed with ADHD and should have very few symptoms of inattention and hyperactivity/impulsivity.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~completed at baseline and each experimental appointment over a period of three weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and completed at baseline and each experimental appointment over a period of three weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Addiction Research Center Inventory (ARCI) for Adderall vs. Placebo
Change in Continuous Performance Test - Identical Pairs (CPT-IP) for Adderall vs. Placebo
Change in Digit Span for Adderall vs. Placebo
+4 more
Secondary outcome measures
DSM-5 ADHD Symptoms Checklist - Modified (DSM 5-M)
Depression, Anxiety, and Stress Scale-Modified (DASS-M)
Pittsburgh Sleep Quality Index-Modified (PSQI-M)
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stimulant MedicationExperimental Treatment2 Interventions
Participants will be administered a stimulant medication (Adderall IR 10mg). The ordering of experimental vs. placebo appointments will be counterbalanced. Participants will complete computer-based tests of sustained attention and working memory during all appointments.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

University of WyomingLead Sponsor
17 Previous Clinical Trials
1,397 Total Patients Enrolled
1 Trials studying Working Memory
48 Patients Enrolled for Working Memory
Cynthia M Hartung, Ph.D.Principal Investigator - University of Wyoming
University of Wyoming
1 Previous Clinical Trials
48 Total Patients Enrolled
1 Trials studying Working Memory
48 Patients Enrolled for Working Memory

Media Library

Adderall IR 10mg (Central Nervous System Stimulant) Clinical Trial Eligibility Overview. Trial Name: NCT03935646 — Phase 2
Working Memory Research Study Groups: Stimulant Medication
Working Memory Clinical Trial 2023: Adderall IR 10mg Highlights & Side Effects. Trial Name: NCT03935646 — Phase 2
Adderall IR 10mg (Central Nervous System Stimulant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03935646 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What primary conditions are stimulant medications most commonly prescribed to address?

"Stimulant Medication can provide relief to those with diseases, chronic pain, and Attention Deficit Hyperactivity Disorder."

Answered by AI

Are individuals under twenty years of age admissible to this experimentation?

"This trial is open to individuals between 18 and 30 years of age. For those younger or older than this range, there are 113 trials for minors and 56 pertaining to seniors."

Answered by AI

Are stimulant medications authorized by the FDA?

"Our team at Power assigned a 2 out of 3 to Stimulant Medication, due to the existing safety data but lack thereof regarding efficacy in Phase 2 trials."

Answered by AI

Who can become a participant in this trial?

"To be considered for participation, applicants must have a documented history of stimulant abuse and fall between the ages 18-30. A total of 40 people are being recruited to this trial."

Answered by AI

Are there any other research initiatives exploring the use of Stimulant Medication?

"Currently, 11 clinical studies are investigating Stimulant Medication with 2 trials within Phase 3. Although the majority are situated in Lexington, Kentucky, a total of 15 locations across America have begun their own respective investigations."

Answered by AI

Is recruitment still underway for this investigation?

"Unfortunately, this trial is no longer actively searching for participants. Initially posted on February 11th 2020 and later edited on July 22nd 2020, the study has fulfilled its recruitment quota. However, if you are looking for other trials related to stimulant abuse or medication, there are currently 187 studies recruiting patients and 11 clinical trials actively accepting applicants."

Answered by AI

To what extent is this trial being populated by volunteers?

"This investigation is no longer accepting candidates. Initially posted on the 11th of February 2020, and updated for the last time on July 22nd 2020, it has since closed to additional participants. For those searching for alternate studies, there are currently 187 trials concerning stimulant abuse actively recruiting individuals and a further 11 studies exploring Stimulant Medication looking for volunteers."

Answered by AI

What are the main aims of this experiment?

"This medical trial, evaluated over a three week period, seeks to observe the alterations in Spatial Span (SS) due to Adderall treatment compared with placebo. The secondary objectives include administering surveys for Depression, Anxiety and Stress Scale-Modified (DASS-M), Pittsburgh Sleep Quality Index-Modified (PSQI-M), and Side Effects Rating Scale - Modified assessing emotional experiences of depression, anxiety, stress levels as well as sleep functioning such as subjective quality, latency and efficiency from "yesterday" until bedtime."

Answered by AI

Who else is applying?

What state do they live in?
Tennessee
North Carolina
How old are they?
18 - 65
What site did they apply to?
University of Wyoming
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria

How responsive is this trial?

Most responsive sites:
  1. University of Wyoming: < 24 hours
Average response time
  • < 1 Day
Typically responds via
Phone Call
~8 spots leftby Apr 2025